Anti-mutated KRAS T-Cell receptors - Kite PharmaAlternative Names: anti-KRAS-G12D-mutation
Latest Information Update: 17 Dec 2016
At a glance
- Originator Kite Pharma; National Cancer Institute (USA)
- Class T lymphocyte cell therapies
- Mechanism of Action T-cell receptor antigen antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Colorectal cancer